Skip to main content
NVDA+0.39%AAPL+0.05%GOOGL-0.63%MSFT+0.08%AMZN+0.35%TSM-3.01%SPCX-4.19%META-0.02%AVGO-4.35%TSLA+0.03%SKHY-4.35%MU+0.36%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%ABBV+0.39%0700.HK-2.19%1398.HK-0.13%CSCO-2.13%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%UNH-1.34%1816.HK+4.26%3988.HK+0.67%GE+0.66%0005.HK-4.87%HSBA.L-1.95%PM+4.05%0857.HK+2.50%0939.HK+0.31%NFLX+2.68%1288.HK+0.15%MS-1.20%EURCAD-0.55%CADCHF+0.52%AUDCHF+0.47%USDTRY+0.44%GBPTRY+0.41%EURAUD-0.41%NZDCAD-0.40%EURUSD-0.36%EURJPY-0.36%USDCHF+0.34%GBPHKD+0.32%CHFJPY-0.32%GBPMXN-0.28%USDTHB+0.28%EURGBP-0.27%AUDNZD+0.27%GBPCAD-0.27%GBPCHF+0.25%NZDUSD-0.22%CADJPY+0.21%NZDJPY-0.19%USDCAD-0.18%GBPAUD-0.17%USDILS+0.16%AUDCAD-0.14%EURNZD-0.13%GBPNZD+0.13%NZDCHF+0.13%AUDJPY+0.12%GBPUSD-0.09%GBPJPY-0.08%AUDUSD+0.05%USDCOP-0.04%EURCHF-0.03%USDMXN+0.03%USDJPY+0.03%CHFSGD+0.03%NZDSGD-0.03%USDZAR+0.02%USDSGD+0.02%USDCNH-0.01%EURSGD+0.01%GBPSGD+0.01%SGDJPY-0.01%USDHKD+0.01%NZDMXN-0.01%AUDSGD+0.01%EURNOK0.00%USDSEK0.00%EURSEK0.00%GBPZAR0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%USDPLN0.00%EURPLN0.00%PLNJPY0.00%NOKJPY0.00%USDNOK0.00%EURCZK0.00%USDDKK0.00%GAGUSD+0.33%XAGUSD+0.33%XNGUSD+0.32%XPTUSD+0.25%HG1+0.21%USOIL-0.19%GAUUSD+0.12%XAUUSD+0.12%W10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-1.71%ETHUSD+11.79%USDTUSD-0.02%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.70%ZECUSDT-10.42%DOGEUSD+5.25%XMRUSDT-2.59%LINKUSD+7.35%XLMUSD-3.65%BCHUSDT-5.32%LTCUSD+1.20%UNIUSD-7.16%SUIUSD-6.85%HBARUSDT-1.87%TONUSD+18.86%TAOUSDT-7.31%AAVEUSD-3.89%DOTUSDT-1.29%ICPUSDT-9.29%ONDOUSDT+2.19%WLDUSDT-7.92%JUPUSDT-5.90%ARBUSDT-6.52%ATOMUSDT+2.17%STXUSDT+2.91%INJUSDT-8.61%FETUSDT-4.77%PYTHUSDT+11.91%TIAUSDT+8.04%SEIUSDT-3.41%IMXUSDT+5.12%GRTUSDT-5.39%OPUSDT-2.03%IOTAUSDT-5.86%WIFUSDT-10.01%AXSUSDT-6.75%POLUSDT-3.95%FARTCOINUSDT-2.57%EOSUSDT+0.74%DYDXUSDT-4.02%GALAUSDT-6.40%ORDIUSDT-6.74%RONINUSDT-4.25%NOTUSDT-5.84%NVDA+0.39%AAPL+0.05%GOOGL-0.63%MSFT+0.08%AMZN+0.35%TSM-3.01%SPCX-4.19%META-0.02%AVGO-4.35%TSLA+0.03%SKHY-4.35%MU+0.36%BRK-B+0.95%LLY-1.61%AMD-3.90%JPM+0.56%WMT+2.22%ASMLa+1.27%V+0.81%XOM+2.75%JNJ-0.76%INTC-5.34%MA+0.82%ABBV+0.39%0700.HK-2.19%1398.HK-0.13%CSCO-2.13%CVX+3.12%COST+0.60%AP2d-0.09%AMAT-2.13%LRCX-2.71%ORCL-5.48%DELL-0.76%BAC+0.17%KO+2.27%CAT-2.17%PG+1.87%UNH-1.34%1816.HK+4.26%3988.HK+0.67%GE+0.66%0005.HK-4.87%HSBA.L-1.95%PM+4.05%0857.HK+2.50%0939.HK+0.31%NFLX+2.68%1288.HK+0.15%MS-1.20%EURCAD-0.55%CADCHF+0.52%AUDCHF+0.47%USDTRY+0.44%GBPTRY+0.41%EURAUD-0.41%NZDCAD-0.40%EURUSD-0.36%EURJPY-0.36%USDCHF+0.34%GBPHKD+0.32%CHFJPY-0.32%GBPMXN-0.28%USDTHB+0.28%EURGBP-0.27%AUDNZD+0.27%GBPCAD-0.27%GBPCHF+0.25%NZDUSD-0.22%CADJPY+0.21%NZDJPY-0.19%USDCAD-0.18%GBPAUD-0.17%USDILS+0.16%AUDCAD-0.14%EURNZD-0.13%GBPNZD+0.13%NZDCHF+0.13%AUDJPY+0.12%GBPUSD-0.09%GBPJPY-0.08%AUDUSD+0.05%USDCOP-0.04%EURCHF-0.03%USDMXN+0.03%USDJPY+0.03%CHFSGD+0.03%NZDSGD-0.03%USDZAR+0.02%USDSGD+0.02%USDCNH-0.01%EURSGD+0.01%GBPSGD+0.01%SGDJPY-0.01%USDHKD+0.01%NZDMXN-0.01%AUDSGD+0.01%EURNOK0.00%USDSEK0.00%EURSEK0.00%GBPZAR0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%USDPLN0.00%EURPLN0.00%PLNJPY0.00%NOKJPY0.00%USDNOK0.00%EURCZK0.00%USDDKK0.00%GAGUSD+0.33%XAGUSD+0.33%XNGUSD+0.32%XPTUSD+0.25%HG1+0.21%USOIL-0.19%GAUUSD+0.12%XAUUSD+0.12%W10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-1.71%ETHUSD+11.79%USDTUSD-0.02%XRPUSD+5.55%SOLUSD+1.82%TRXUSDT-0.70%ZECUSDT-10.42%DOGEUSD+5.25%XMRUSDT-2.59%LINKUSD+7.35%XLMUSD-3.65%BCHUSDT-5.32%LTCUSD+1.20%UNIUSD-7.16%SUIUSD-6.85%HBARUSDT-1.87%TONUSD+18.86%TAOUSDT-7.31%AAVEUSD-3.89%DOTUSDT-1.29%ICPUSDT-9.29%ONDOUSDT+2.19%WLDUSDT-7.92%JUPUSDT-5.90%ARBUSDT-6.52%ATOMUSDT+2.17%STXUSDT+2.91%INJUSDT-8.61%FETUSDT-4.77%PYTHUSDT+11.91%TIAUSDT+8.04%SEIUSDT-3.41%IMXUSDT+5.12%GRTUSDT-5.39%OPUSDT-2.03%IOTAUSDT-5.86%WIFUSDT-10.01%AXSUSDT-6.75%POLUSDT-3.95%FARTCOINUSDT-2.57%EOSUSDT+0.74%DYDXUSDT-4.02%GALAUSDT-6.40%ORDIUSDT-6.74%RONINUSDT-4.25%NOTUSDT-5.84%
ER

Erasca, Inc. (ERAS)

NASDAQ • Healthcare

$15.46
+$1.34 (+9.5%)
Market closed

Last close at October 8, 2026 at 20:00 UTC

Open$13.96
Day Range$13.78 - $15.62
Avg. Volume (3M)5.1M
Market Cap$5.3B
52 Week Range
$2.11$24.28
Next EarningsIn 34 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$287.2M
EPS (TTM)
-$0.95
ROA (TTM)
-66.02%
Current Ratio
8.29

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+9.1%Q1 2026-$0.1
-438.0%Q2 2026-$0.6
-25.7%Q3 2026-$0.14
Next

Nov 11

in 34 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -25.7%

Erasca’s EPS trailed consensus in the second fiscal quarter of 2026, with preliminary results reported August 12 showing EPS of -$0.14 versus a -$0.11 estimate, -26%, and down 16.7% from -$0.12 a year ago. Operating loss came to about $47.6 million, net income was negative roughly $44.1 million, down 30.1% from negative $33.9 million a year earlier, and operating cash flow was negative about $27.3 million. Consensus for the next period calls for EPS of USD -0.13.

View full earnings history

About Erasca, Inc.

Erasca, Inc. is a NASDAQ-listed biotechnology company developing cancer therapies aimed at tumors driven by the RAS/MAPK pathway. The company operates as an early-stage drug developer in the healthcare sector and has built its business around a pipeline of candidates for difficult-to-treat malignancies.

Name
Erasca, Inc.
CEO
Jonathan E. Lim
Website
www.erasca.com
Industry
Healthcare
Year Founded
2018
Employees
103

Today's Snapshot

AI-generated

The day ended with ERAS 9.5% higher at 15.46, while its sector was flat. Shares changed hands at roughly twice its usual level.

Trading Volume

Above 10d avg 5.0M

9.5M

vs S&P 500 Today

Strong Outperformance

+10.03%

Updated: October 8, 2026 at 20:26 UTC

ERAS Headlines

Biotech & AI Fuel Big Stock Moves

January 20, 2026

5 min read
View All News

Technical Indicators

3 Buy3 Neutral2 Sell
ERAS at $15.46 exhibits a neutral setup as short-term averages sit near the price while medium-term averages provide resistance, even though the 200-day level is beneath the market. Momentum is mixed with a neutral RSI and a slightly negative MACD, and ADX around the high teens signals limited trend strength. Volatility is comparatively elevated per ATR and on-balance volume shows distribution, while the classic pivot is below the current price providing some near-term support. Technical takeaway: Neutral — short-term strength is offset by medium-term resistance and a weak volume profile.
All signals
  • EMA (5 indicators)$12.96 - $15.91
    Buy
  • RSI (14)51.06
    Neutral
  • Stochastic %K (14, 3, 3)46.32
    Neutral
  • MACD Level (12, 26)-0.55
    Neutral

Peers & Related Assets

RVMDRevolution Medicines, Inc.
$188.12-6.3%
TNGXTango Therapeutics, Inc.
$22.57+3.4%
IDYAIDEAYA Biosciences, Inc.
$36.06-0.6%
NUVBNuvation Bio Inc.
$4.95+1.9%
ORICORIC Pharmaceuticals, Inc.
$12.03+0.2%
KURAKura Oncology, Inc.
$10.52-1.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.